Prestige BioPharma and Pharmapark LLC today announced that the two companies have entered into a binding agreement for the exclusive partnership and supply for the commercialization of Prestige BioPharma´s Trastuzumab biosimilar in the Russian Federation.
Intas Pharmaceuticals announced Wednesday that it launched its trastuzumab biosimilar, under the brand name Eleftha, in India, reported Business Standard.